Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 2, 1999, Pages 329-334

  Jorgensen, J H ^a   Weigel, L M ^b   Ferraro, M J ^c   Swenson, J M ^b   Tenover, F C ^b  

^a Univ of Texas Health Science Center ^*  (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINAFLOXACIN; GENE PRODUCT; GREPAFLOXACIN; LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; GENE LOCUS; GENE MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0033053495     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.2.329     Document Type: Article

References (29)

1. Balas, D., E. Fernandez-Moreira, and A. G. DeLaCampa. 1998. Molecular characterization of the gene encoding the DNA gyrase A subunit of Streptococcus pneumoniae. J. Bacteriol. 180:2854-2861.
2. Barry, A. L., P. C. Fuchs, S. D. Allen, S. D. Brown, J. H. Jorgensen, and F. C. Tenover. 1996. In-vitro susceptibility of Streptococcus pneumoniae to the d-and l-isomers of ofloxacin: interpretive criteria and quality control limits. J. Antimicrob. Chemother. 37:365-369.
3. Barry, A. L., M. A. Pfaller, P. C. Fuchs, and R. R. Packer. 1994. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrob. Agents Chemother. 38:2419-2425.
4. Bedos, J.-P., V. Rieux, J. Bauchet, M. Muffat-Joly, C. Carbon, and E. Azoulay-Dupuis. 1998. Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob. Agents Chemother. 42:862-867.
5. Bernard, L., J.-C. Nguyen Van, and J.-L. Mainardi. 1995. In vivo selection of Streptococcus pneumoniae resistant to quinolones, including sparfloxacin. Clin. Microbiol. Infect. 1:60-61.
6. Breiman, R. F., J. C. Butler, F. C. Tenover, J. Elliott, and R. R. Facklam. 1994. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 271:1831-1835.
7. Butler, J. C., J. Hofmann, M. S. Cetron, J. A. Elliott, R. R. Facklam, R. F. Breiman, and the Pneumococcal Sentinel Surveillance Working Group. 1996. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's pneumococcal sentinel surveillance system. J. Infect. Dis. 174: 986-993.
8. Doern, G. V., A. Brueggemann, H. P. Holley, Jr., and A. M. Rausch. 1996. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob. Agents Chemother. 40:1208-1213.
9. Feikin, D., M. Cetron, A. Schuchat, R. Facklam, J. Jorgensen, M. Kolczak, and Active Surveillance Team. 1997. Multistate population-based assessment of drug-resistant S. pneumoniae mortality. In Program and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America.
10. Goldstein, F. W., J. F. Acar, and the Alexander Project Collaborative Group. 1996. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae; results of a 1992-1993 Western Europe and USA collaborative surveillance study. J. Antimicrob. Chemother. 38(Suppl. A): 71-84.
11. Gootz, T. D., and K. E. Brighty. 1996 Fluoroquinolone antibacterials: SAR. mechanism of action, resistance, and clinical aspects. Med. Res. Rev. 16: 433-486.
12. Gootz, T. D., R. Zaniewski, S. Haskell, B. Schmieder, J. Tankovic, D. Girard, P. Courvalin, and R. J. Polzer. 1996. Activity of the new fluoroquinolone trovafloxacin (CP-99, 219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob. Agents Chemother. 40:2691-2697.
13. Janoir, C., V. Zeller, M.-D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
14. Jorgensen, J. H., M. L. McElmeel, S. A. Crawford, M. Cetron, and R. F. Breiman. 1996. Streptogramin and fluoroquinolone resistance among recent North American isolates of Streptococcus pneumoniae, abstr. C84, p. 49. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Jorgensen, J. H., J. M. Swenson, F. C. Tenover, M. J. Ferraro, J. A. Hindler, and P. R. Murray. 1994. Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae. J. Clin. Microbiol. 32:2448-2459.
16. Margerrison, E. E. C., R. Hopewell, and L. M. Fisher. 1992. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J. Bacteriol. 174:1596-1603.
17. McDougal, L. K., J. K. Rasheed, J. W. Biddle, and F. C. Tenover. 1995. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob. Agents Chemother. 39:2282-2288.
18. Moroney, J., A. Fiore, M. Farley, L. Harrison, J. Patterson, M. Cetron, and A. Schuchat. 1997. Therapy and outcomes of meningitis caused by drug-resistant Streptococcus pneumoniae (SP) in three U.S. cities, 1994-1996. In Program and abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America.
19. Muñoz, R., and A. G. de la Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
20. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. National Committee for Clinical Laboratory Standards. 1998. Performance standards for antimicrobial susceptibility testing. Eighth informational supplement M100-S8. National Committee for Clinical Laboratory Standards. Wayne, Pa.
23. Pan, X.-S., J. Ambler, S. Mehtar, and L. M. Fisher. 1996. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2321-2326.
24. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
25. Pan, X.-S., and L. M. Fisher. 1997. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 40:471-474.
26. Perichon, B., J. Tankovic, and P. Courvalin. 1997. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1166-1167.
27. Simor, A. E., M. Louie, The Canadian Surveillance Network, and D. E. Low. 1996. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40:2190-2193.
28. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1996. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
29. Thornsberry, C., P. Ogilvie, J. Kahn, and Y. Mauriz. 1997. Surveillance of antimicrobial resistance in Streptococcus pneumoniae. Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn. Microbiol. Infect. Dis. 29:249-257.